Impurity Control — ICH Q3D(R2)

Elemental Impurities Risk Assessment: The Complete Guide

A practical walkthrough of ICH Q3D — element classification, PDE-based limit calculation, and how to build a defensible, risk-based control strategy instead of testing everything.

Why ICH Q3D Replaced the Old Heavy Metals Test

For over a century, pharmacopeial heavy metals testing relied on a non-specific colorimetric precipitation test — prone to poor recovery, matrix interference, and reliance on a skilled analyst's visual judgment. ICH Q3D, alongside USP <232>/<233> and Ph. Eur. 5.20, replaced this with a risk-based framework built on instrumental techniques (ICP-MS, ICP-OES) and element-specific Permitted Daily Exposure (PDE) limits.

Critically, Q3D does not mandate testing for all 24 listed elements in every product — it requires a documented risk assessment to identify which elements are plausible contaminants for a given drug product, based on its raw materials, manufacturing equipment, and container-closure system.

🔬

Measuring Elemental Impurities in Pharmaceuticals: A Practical Guide

Robert Thomas — a complete, reader-friendly walkthrough of ICP-MS/ICP-OES methodology, J-value validation, and instrument selection for USP <233> testing.

As an Amazon Associate I earn from qualifying purchases.

Element Classification

Class	Description	Testing Approach
Class 1	As, Cd, Pb, Hg — significant human toxicants, limited pharmaceutical use	Assess in all potential sources regardless of route
Class 2A	Co, Ni, V — relatively high probability of occurrence	Assess in all potential sources
Class 2B	Ag, Au, Ir, Os, Pd, Pt, Rh, Ru, Se, Tl — low probability unless intentionally added (e.g., catalysts)	Assess only if intentionally added or otherwise plausible
Class 3	Ba, Cr, Cu, Li, Mo, Sb, Sn — comparatively low toxicity via oral route	Assess for parenteral/inhalation more rigorously than oral

Class 1 Oral PDE Reference (Commonly Cited Values)

Element	Oral PDE (µg/day)
Arsenic (As)	15
Cadmium (Cd)	5
Lead (Pb)	5
Mercury (Hg)	30

Always verify current PDE values against the latest ICH Q3D(R2) guideline text before use — this table covers only the four Class 1 elements as a quick reference, not the full 24-element list.

Interactive Tool: PDE-to-Concentration Limit Calculator

Once the relevant PDE is identified, it is converted into a practical concentration limit for the drug product — the same basic conversion logic used for nitrosamines and other impurity classes.

Concentration Limit (µg/g or ppm) = PDE (µg/day) / Maximum Daily Dose (g/day)

Element PDE (µg/day)

Maximum Daily Dose (g/day)

Concentration Limit

—

Daily Exposure at Limit

—

Applies the option 2a/2b style calculation from ICH Q3D for a single component contributing the full PDE. If multiple components (API, excipients) each contribute, allocate the PDE proportionally across all potential sources rather than applying the full PDE to one component alone.

🔗 Related: Nitrosamine AI-to-Limit Calculator 🔗 Related: FMEA Risk Priority Number Calculator 🔗 Related: Confidence/Reliability Sample Size Calculator

Building the Risk Assessment

Step	Focus
1. Identify potential sources	API synthesis route/catalysts, excipients, water, manufacturing equipment, container-closure system
2. Determine which elements are plausible	Cross-reference sources against the Class 1/2A/2B/3 list — not every element applies to every product
3. Estimate or measure levels	Use supplier data, historical testing, or new ICP-MS/ICP-OES testing where data is lacking
4. Compare against PDE-derived limits	Apply the concentration limit calculation above for each plausible element
5. Establish control strategy	Specification testing, supplier control, or justified omission of testing where risk is negligible

📘

Quality Risk Management in the FDA-Regulated Industry, 2nd Ed.

José Rodríguez-Pérez — the ICH Q9 risk assessment structure behind the Q3D element identification and control strategy process.

As an Amazon Associate I earn from qualifying purchases.

Specimen Quality Form

A starting template for documenting an element-by-element risk screening — fill it in below, then transcribe into your controlled document system.

Specimen — Elemental Impurity Source Assessment Record

Drug Product / Component

Route of Administration

Potential Sources Reviewed

Elements Identified as Plausible (Class / Element)

Testing Required? (Y/N)

Justification if No Testing

Assessed By / Date

QA Approval / Date

Common Pitfalls

Pitfall	Fix
Testing all 24 elements "to be safe"	Wastes resources — Q3D expects a targeted, risk-justified list, not blanket testing
Ignoring container-closure contribution	Metal/rubber components can contribute elemental impurities — include in the source review
Applying full PDE to every component	Allocate PDE proportionally when multiple components could each contribute the same element
No periodic reassessment	Reassess when raw material suppliers, synthesis routes, or packaging change

📗

Pharmaceutical Process Validation: An International Third Edition

Robert A. Nash & Alfred H. Wachter (eds.) — covers analytical method validation principles (ICH Q2) directly applicable to validating your ICP-MS/ICP-OES elemental impurity method.

As an Amazon Associate I earn from qualifying purchases.

📕

Genotoxic Impurities: Strategies for Identification and Control

Andrew Teasdale (ed.) — while focused on organic genotoxic impurities, its TTC/PDE limit-setting logic mirrors the concentration-limit math used throughout ICH Q3D.

As an Amazon Associate I earn from qualifying purchases.

This guide is an educational overview. Always confirm current PDE values, element classifications, and testing expectations against the latest published ICH Q3D(R2) guideline and applicable pharmacopeial chapters before finalizing a control strategy.